САХАРНЫЙ ДИАБЕТ 2 ТИПА И СОПУТСТВУЮЩИЕ ЗАБОЛЕВАНИЯ: ПРЕИМУЩЕСТВА ПРИМЕНЕНИЯ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-4 САКСАГЛИПТИНА (ОНГЛИЗА®)
- Авторы: Анциферов М.Б.1, Петунина Н.А.2, Antsiferov MB3, Petunina NA3
-
Учреждения:
- Эндокринологический диспансер Департамента здравоохранения г. Москвы
- ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФ
- Выпуск: № 3 (2012)
- Страницы: 22-28
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279281
- ID: 279281
Цитировать
Полный текст
Аннотация
Об авторах
Михаил Борисович Анциферов
Эндокринологический диспансер Департамента здравоохранения г. Москвыдоктор медицинских наук, профессор, главный врач Эндокринологического диспансера Департамента здравоохранения Москвы; Эндокринологический диспансер Департамента здравоохранения г. Москвы
Нина Александровна Петунина
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФдоктор медицинских наук, профессор, заведующая кафедрой эндокринологии и диабетологии ФППО ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФ; ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФ
M B Antsiferov
N A Petunina
Список литературы
- Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
- American Association of Clinical Endocrinologists. State of diabetes complications in America: a comprehensive report issued by the American Association of Clinical Endocrinologists. 2007. http://multivu.prnewswire.com/mnr/AACE/2007/docs/ Diabetes_ Complications_Report.pdf. Accessed April 2, 2010.
- Khazai NB, Beck GR Jr, Umpierrez GE. Diabetes and fractures: an overshadowed association. Curr Opin Endocrinol Diabetes Obes 2009;16(6):435-45.
- American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(1):S11-S61.
- Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203.
- Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15(6):541-59.
- Алгоритмы специализированной помощи больным сахарным диабетом. 2011. Вып. 5.
- National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S1-S180.
- Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-443.
- Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007;370:1129-136.
- Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Metaanalysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med 2010;170:1191-201.
- Boulton DW, Geraldes M. Safety, tolerabilty, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract no. 606-P plus poster]. 67th Scientific Sessions of the American Diabetes Association. Chicago (IL), 2007 Jun 22-26.
- Kim YB, Kopcho LM, Kirby MS, et al. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipepti-dyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006;445:9-18.
- Dhillon S, Weber J. Saxagliptin. Drugs 2009;69 (15):2103-114.
- Maheux P, et al. Efficacy of Saxagliptin in Relation to Baseline HbA1c in a Pooled Analysis of Three Add-on Pivotal Randomised Phase 3 Clinical Trials. EASD 2010:825.
- Food and Drug Administration: Guidance for Industry. Diabetes Mellitus-Evaluation Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071627.pdf. Accessed September 2010.
- Food and Drug Administration, Center of Drug Evaluation and Research. Endocrinologic and metabolic drugs advisory committee meeting: summary minutes. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM192026.pdf. Accessed April 1, 2009.
- Wolf R, Frederich R, Fiedorek F, et al. Evaluation of CV risk in saxagliptin clinical trials. 8-LB poster. 69th Annual Scientific Sessions of the American Diabetes Association. New Orleans (LA), 2009 Jun 5-9.
- Bristol-Myers Squibb, AstraZeneca. Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes. March 2010 (press release) http://www.news-medical.net/news/20100310/Bristol-Myers-Squibb-AstraZeneca-commence-SAVOR-TIMI-53-trial-of-ONGLYZA-for-type-2-diabetes.aspx.
- Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
- Center for Disease Control. National diabetes fact sheet 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed January 10, 2011.
- Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
- Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clinical Therapeutics 2009;31(11):2608-617.
- Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-047.
- Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2010;19.
- Boulton D, Tang A, Patel C, et al. Pharmacokinetics of dipeptidylpepetidase-4 inhibitor saxagliptin in subjects with renal impairment [abstract no. P357]. 11th European Congress of Endocrinology, Istanbul, 2009 Apr 25-29.
- Nowicki M, et al. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment compared with placebo. Diabetes Obes Metab 2011;13(6):523-32.
- Rosenstock J, Gross J, Salinas C, et al. Long-Term Safety and Efficacy of Saxagliptin After 4-Year Follow-Up of Patients With Type 2 Diabetes. ADA 2011:1086.
- Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94.
- Lenhard JM, Croom DK, Minnick DT, et al. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Comm 2004;324:92-97.
- Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1705-25.
- Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. C M A J 2005;172(7):899-905.
- Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
- Patel C, Castaneda L, Frevert U, et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract no. 537-P]. Diabetes 2008;57(1):A160.
- Göke B, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64(12):1619-31.
- Göke B, et al. Saxagliptin vs Glipizide as Add-On Therapy to Metformin for Type 2 Diabetes Mellitus (T2DM): Long-Term Safety and Efficacy. ADA 2011:1110.
- Rao A, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care 2008;31:1672-78.